coronavirus

In his weekly clinical update, Dr. Griffin discusses the effectiveness of maternal mRNA COVID-19 vaccination during pregnancy against COVID-19–associated hospitalizations in infants aged <6 months during SARS-CoV-2 Omicron predominance, COVID-19 vaccination recommendations and practices for women of reproductive age by health care providers, molnupiravir for intra-household prevention of COVID-19, delayed peak SARS-CoV-2 viral loads relative to symptom onset and implications for COVID-19 testing programs, viral kinetics of sequential SARS-CoV-2 infections, FDA authorizes updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variants, antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors, SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, and the efficacy of gabapentin For post-COVID-19 olfactory dysfunction.

In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK.

In his weekly clinical update, Dr. Griffin discusses wastewater surveillance data as a complement to emergency department visit data for tracking the incidence of influenza A and RSV, chatbot-delivered online intervention to promote seasonal Influenza vaccination during the COVID-19 pandemic, temporal assessment of disparities in California COVID-19 mortality by industry, modeling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City, can high COVID-19 vaccination rates in adults help protect unvaccinated children, Nirmatrelvir/Ritonavir use and hospitalizations or death in previously uninfected non-hospitalized high-risk population with COVID-19, Optimal duration of systemic corticosteroids in COVID-19 treatment, and vaccination after developing long COVID.

In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection.

In his weekly clinical update, Dr. Griffin discusses China’s health authorities fighting surge in cases of Mpox unknown origin, analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses in primary care practices, prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza, comparison of bivalent and monovalent mRNA vaccine boosters, optimal duration of systemic corticosteroids in COVID-19 treatment, acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization, temporal changes in fecal microbiota of patients infected with COVID-19, and long-term survival after intensive care for COVID-19.